← SynDRA
EGANELISIB
SynDRA canonical compound SYN0038680 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | PIK3CG |
|---|
| Mechanism of action | PI3K inhibitor |
|---|
All known targets
- PIK3CG
- PIK3CA
- PIK3CB
- PIK3CD
Mechanisms of action (all sources)
- PIK3CG INHIBITOR
- PI3-kinase p110-gamma subunit inhibitor
- PIK3CA INHIBITOR
- PIK3CB INHIBITOR
- PIK3CD INHIBITOR
- PI3K inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PIK3CA
- PIK3CB
- PIK3CD
- PRKDC
- CYP1A2
- CYP2B6
- CYP2C19
- CYP2C8
- CYP2C9
- CYP2D6
- CYP3A4
- KCNH2
- PIK3C3
- SIK1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- KSYK
- NSD2
- PIK3C2B
- PIK3C2G
- PIK3R1
- PK3CA
- PK3CB
- PK3CD
- SYK
Cross-references
Synonyms
- IPI-549
- Pi3k-gamma inhibitor ipi-549
- IPI 549
- XUMALORDVCFWKV-IBGZPJMESA-N
- IPI549
- CHEMBL3984425
- GTPL9563
- SCHEMBL16629991
- MolPort-044-756-207
- EX-A1057
- s8330
- BDBM50192880
- ZINC584906867
- AKOS030627132
- CS-6106
- compound 26 [PMID: 27660692]
- AC-29898
- HY-100716
- Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-
- 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
- (S)-2-amino-N-(1-(8-((
- pi3k-gamma Inhibitor IPI-549
- FOF5155FMZ
- RefChem:136348
- DTXCID301766789
- Eganelisib [USAN]
- MFCD30533720
- IPI 549-d5
- Eganelisib (USAN)
- EGANELISIB [INN]
- Eganelisib (IPI-549)
- UNII-FOF5155FMZ
- EGANELISIB [WHO-DD]
- orb1301794
- SCHEMBL29493096
- C30H24N8O2
- GLXC-10717
- TSC75851
- V7Y
Look up EGANELISIB in the interactive SynDRA portal →